CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Memokath 028SW Urethral Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00252941
NCT00252941Phase 2Completed
CompareCT.gov

The Role Of Prophylactic Urethral Stenting With Memokath® 028SW in Patients Undergoing Prostate 125I Seed Implants For Prostate Carcinoma: A Phase I/II Study

The Cleveland Clinic·interventional·Posted Nov 15, 2005·Updated Dec 21, 2010

In Brief

A Phase 2 clinical trial evaluating Memokath 028SW Urethral Stent for Prostate Cancer and Post-Brachytherapy Bladder Outlet Obstruction. Completed, across 1 site.

Detailed Summary

The purpose of this study is to determine the feasibility, safety, and efficacy of the Memokath® 028SW stent to prevent urinary obstructive symptoms (difficulty urinating) when used after prostate seed implantation for the treatment of localized prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Post-Brachytherapy Bladder Outlet Obstruction
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 15, 2005
Enrollment StartNov 1, 2005
Primary CompletionApr 1, 2006
Study CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 20.6 years ago

Interventions

Memokath 028SW Urethral Stentdevice